Top Markets
#1 Zora Zora +42.47%
#2 AI XOVIA AI XOVIA +37.42%
#3 0G 0G +21.07%
#4 Full Moon Full Moon +19.35%
#5 Axelar Axelar +14.32%
#6 Notcoin Notcoin +13.85%
#7 ZKsync ZKsync +12.68%
#8 Wrapped NXM Wrapped NXM +12.14%
#9 rsERG rsERG +12.06%
#10 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +10.43%
Coin of the day
Zora Zora
Settings
Language
ENGLISH
Currency
USD
Theme
Kexing Biopharm Co., Ltd. Kexing Biopharm Co., Ltd.

Kexing Biopharm Co., Ltd.

688136
Rank in Stocks #12397
Kexing Biopharm Co., Ltd. is a global pharmaceutical enterprise primarily... Kexing Biopharm Co., Ltd. is a global pharmaceutical enterprise primarily involved in the exploration, manufacturing, and commercialization of advanced recombinant protein-based drugs and microbial preparations, serving both the Chinese domestic market and international clientele. The company strategically directs its research and development endeavors towards crucial medical areas, specifically focusing on antiviral therapies, oncology, immunology, hematological conditions, digestive system health, and degenerative diseases. Its extensive product lineup features diverse pharmaceutical solutions. This includes innovative recombinant human proteins such as interferon a1b, erythropoietin, and granulocyte stimulating factor. Additionally, their offerings encompass microbial formulations like Clostridium butyricum combined live bacteria powder, traditional Chinese patent medicines (e.g., Kehuang Capsule), and chemical drugs like Entecavir. Kexing Biopharm also provides cutting-edge biologics, including liraglutide (a human glucagon-like peptide-1), along with other specialized therapeutics such as Albumin-Paclitaxel, Infliximab, Bevacizumab, adalimumab, trastuzumab, neratinib maleate tablets, and lenalidomide capsules. Established in 1989, the company's main operations are situated in Jinan, China.
Share Price
$2.97
Market Cap
$590.25M
Change (1 day)
-5.00%
Change (1 year)
-52.18%
Country
CN
Trade Kexing Biopharm Co., Ltd. (688136)

Category

Healthcare
P/E ratio for Kexing Biopharm Co., Ltd. (688136)
P/E ratio as of 2026 TTM: 0
According to Kexing Biopharm Co., Ltd. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Kexing Biopharm Co., Ltd. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.